WO1998035693A3 - Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease - Google Patents
Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease Download PDFInfo
- Publication number
- WO1998035693A3 WO1998035693A3 PCT/IB1998/000781 IB9800781W WO9835693A3 WO 1998035693 A3 WO1998035693 A3 WO 1998035693A3 IB 9800781 W IB9800781 W IB 9800781W WO 9835693 A3 WO9835693 A3 WO 9835693A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- naip
- detection
- treatment
- iap
- iaps
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70746/98A AU7074698A (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease |
AT98917563T ATE223727T1 (en) | 1997-02-13 | 1998-02-13 | DETECTION AND MODULATION OF IAPS AND NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISEASES |
EP98917563A EP0991421B1 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
JP53132598A JP2002512602A (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of IAPs and NAIP for diagnosis and treatment of proliferative diseases |
CA2273821A CA2273821C (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
DE69807878T DE69807878T2 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of IAPS and NAIP for the diagnosis and treatment of proliferative diseases |
DK98917563T DK0991421T3 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of IAPs and NAIP in the diagnosis and treatment of proliferative disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/800,929 | 1997-02-13 | ||
US08/800,929 US6133437A (en) | 1997-02-13 | 1997-02-13 | Modulation of IAPs for the treatment of proliferative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998035693A2 WO1998035693A2 (en) | 1998-08-20 |
WO1998035693A3 true WO1998035693A3 (en) | 1998-10-15 |
Family
ID=25179735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1998/000781 WO1998035693A2 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
Country Status (11)
Country | Link |
---|---|
US (7) | US6133437A (en) |
EP (2) | EP0991421B1 (en) |
JP (1) | JP2002512602A (en) |
AT (1) | ATE223727T1 (en) |
AU (1) | AU7074698A (en) |
CA (1) | CA2273821C (en) |
DE (1) | DE69807878T2 (en) |
DK (1) | DK0991421T3 (en) |
ES (1) | ES2182297T3 (en) |
PT (1) | PT991421E (en) |
WO (1) | WO1998035693A2 (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030073159A1 (en) * | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US5958771A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US20030083300A1 (en) * | 1998-12-03 | 2003-05-01 | Bennett C Frank | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US5958772A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
US6156535A (en) * | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
GB9601108D0 (en) * | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US6511828B1 (en) | 1996-05-31 | 2003-01-28 | Arch Development Corporation | Human and drosophila inhibitors of apoptosis proteins (IAPs) |
DE69739105D1 (en) * | 1996-11-20 | 2008-12-24 | Univ Yale | SURVIVIN, A PROTEIN HAS THE CELLULAR APOPTOSIS, AND ITS MODULATION |
US6270980B1 (en) * | 1997-06-05 | 2001-08-07 | Idun Pharmaceuticals, Inc. | Rapid methods for identifying modifiers of cellular apoptosis activity |
US6171821B1 (en) * | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
AU7621700A (en) * | 1999-09-30 | 2001-04-30 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Novel members of the iap gene family |
EP1118334A1 (en) * | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
US20030106084A1 (en) * | 2000-03-29 | 2003-06-05 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
DE60142899D1 (en) * | 2000-06-20 | 2010-10-07 | Dainippon Sumitomo Pharma Co | COMPOUNDS FOR THE TRANSFER OF OLIGONUCLEOTIDES |
WO2002010381A1 (en) * | 2000-07-28 | 2002-02-07 | Merck Patent Gmbh | Novel protein inhibitor of apoptosis proteins |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20050214290A1 (en) * | 2001-03-29 | 2005-09-29 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
WO2002094271A1 (en) * | 2001-05-15 | 2002-11-28 | Faulk Pharmaceuticals, Inc. | Targeted delivery of bioaffecting compounds for the treatment of cancer |
AU2002312543A1 (en) * | 2001-08-01 | 2003-02-17 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
US7704700B2 (en) * | 2002-02-12 | 2010-04-27 | Burnham Institute For Medical Research | Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides |
US7897753B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
NZ546806A (en) * | 2002-03-27 | 2007-03-30 | Aegera Therapeutics Inc | Antisense IAP nucleobase oligomers and uses thereof |
US20050215498A1 (en) * | 2002-05-31 | 2005-09-29 | Guenther Eissner | Method for the protection of endothelial and epithclial cells during chemotherapy |
US20040005565A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of livin expression |
WO2004017991A1 (en) * | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
US20040132554A1 (en) * | 2003-01-02 | 2004-07-08 | Patrick Schulze | Golf tee holder |
US20080199439A1 (en) * | 2003-02-12 | 2008-08-21 | Mclendon George L | IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods |
US7635560B2 (en) * | 2003-04-17 | 2009-12-22 | Genesis Group Inc. | Pygopus in diagnosis and treatment of cancer |
US8012944B2 (en) * | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
WO2005074381A2 (en) * | 2004-01-07 | 2005-08-18 | Rambam Medical Center, Funds For Medical Research Development Of Infrastructure And Health Services | Induction of apoptosis via arts-iap complexes |
TWI350373B (en) * | 2004-01-23 | 2011-10-11 | Oncotherapy Science Inc | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators |
CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
US7252482B2 (en) * | 2004-08-24 | 2007-08-07 | Beckett Corporation | Motor driven pump with improved motor cooling air flow |
CA2584986A1 (en) * | 2004-10-22 | 2006-05-04 | Neurologix, Inc. | Use of apoptosis inhibiting compounds in degenerative neurological disorders |
WO2006060898A1 (en) * | 2004-12-06 | 2006-06-15 | Aegera Therapeutics Inc | Method for treating inflammatory disorders |
JPWO2006082866A1 (en) * | 2005-02-01 | 2008-06-26 | 萬有製薬株式会社 | Method for detecting p53 dysfunction, method for molecular diagnosis of cancer, and method for evaluating compound effective for cancer treatment |
CA2598995C (en) * | 2005-02-25 | 2014-07-15 | Stephen M. Condon | Dimeric iap inhibitors |
TW200741009A (en) * | 2005-07-01 | 2007-11-01 | Oncotherapy Science Inc | Methods of modulating SMYD3 for treatment of cancer |
WO2007021825A2 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
CN101535300B (en) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir domain binding compounds |
WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP2049524A2 (en) * | 2006-07-24 | 2009-04-22 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100113326A1 (en) * | 2006-07-24 | 2010-05-06 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US7985735B2 (en) * | 2006-07-24 | 2011-07-26 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
US7725622B2 (en) * | 2006-11-29 | 2010-05-25 | Townsend Analytics, Ltd. | Data distribution system and method |
JP2010528587A (en) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | Method using expression of TNFα gene as biomarker of sensitivity to apoptosis inhibitor protein antagonist |
WO2009140447A1 (en) | 2008-05-16 | 2009-11-19 | Novartis Ag | Immunomodulation by iap inhibitors |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
WO2012052758A1 (en) * | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
FI20115640A0 (en) * | 2011-06-22 | 2011-06-22 | Turun Yliopisto | combination therapy |
JP6393682B2 (en) | 2012-07-13 | 2018-09-19 | トゥルン イリオピスト | Combination therapy III |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006255A2 (en) * | 1995-08-04 | 1997-02-20 | University Of Ottawa | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
WO1997026331A2 (en) * | 1996-01-19 | 1997-07-24 | University Of Ottawa | Use of neuronal apoptosis inhibitor protein (naip) |
WO1998022131A2 (en) * | 1996-11-15 | 1998-05-28 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665550A (en) * | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5594076A (en) * | 1991-09-24 | 1997-01-14 | The Pennsylvania Research Foundation | Hydrodegradable polyesters |
US6265157B1 (en) * | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
US20030073159A1 (en) * | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
EP0625159B1 (en) * | 1992-09-14 | 2003-03-26 | The General Hospital Corporation | Ikaros: a regulatory gene involved in t-cell differentiation |
US5958772A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
US5958771A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US5718883A (en) * | 1993-04-14 | 1998-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5691179A (en) * | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
CA2181548C (en) * | 1994-01-18 | 2009-11-03 | Carlos F. Barbas, Iii | Zinc finger protein derivatives and methods therefor |
EP0759090A4 (en) * | 1994-04-13 | 2000-05-24 | Jolla Cancer Res Found | Interaction of proteins involved in a cell death pathway |
WO1996012016A1 (en) * | 1994-10-18 | 1996-04-25 | The University Of Ottawa | Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy |
EP0830375A4 (en) * | 1995-05-11 | 2001-11-21 | Human Genome Sciences Inc | Human inhibitor of apoptosis gene 1 |
US5770690A (en) * | 1995-06-27 | 1998-06-23 | Neurex Corporation | Bax omega protein and methods |
US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US5919912A (en) * | 1995-08-04 | 1999-07-06 | University Of Ottawa | Mammalian IAP antibodies and diagnostic kits |
US6187557B1 (en) | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
AU6692996A (en) * | 1995-08-08 | 1997-03-05 | Tularik Inc. | Inhibitors of apoptosis |
US5834216A (en) * | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
US5605022A (en) * | 1995-12-26 | 1997-02-25 | Nci Building Systems, Inc. | Vented closure |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6228603B1 (en) * | 1997-05-22 | 2001-05-08 | The Burnham Institute | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
CA2225187A1 (en) * | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US6417160B1 (en) * | 1997-10-14 | 2002-07-09 | Nadine A. Tatton | Methods for increasing schwann cell survival |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
WO2000021513A2 (en) * | 1998-10-09 | 2000-04-20 | Shankar L Sai Latha | Methods for treating multiple sclerosis |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20020119168A1 (en) * | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
KR100397275B1 (en) * | 2001-03-08 | 2003-09-17 | 주식회사 웰진 | Novel high-throughput system for functional genomics using unidirectional antisense cDNA library |
NZ546806A (en) * | 2002-03-27 | 2007-03-30 | Aegera Therapeutics Inc | Antisense IAP nucleobase oligomers and uses thereof |
BRPI0414886A (en) * | 2003-09-29 | 2006-12-12 | Topigen Pharma Inc | oligonucleotide compositions and methods for treating disease including inflammatory conditions |
-
1997
- 1997-02-13 US US08/800,929 patent/US6133437A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 EP EP98917563A patent/EP0991421B1/en not_active Expired - Lifetime
- 1998-02-13 WO PCT/IB1998/000781 patent/WO1998035693A2/en active IP Right Grant
- 1998-02-13 DE DE69807878T patent/DE69807878T2/en not_active Expired - Lifetime
- 1998-02-13 EP EP02003348A patent/EP1277836A1/en not_active Ceased
- 1998-02-13 DK DK98917563T patent/DK0991421T3/en active
- 1998-02-13 PT PT98917563T patent/PT991421E/en unknown
- 1998-02-13 AT AT98917563T patent/ATE223727T1/en active
- 1998-02-13 JP JP53132598A patent/JP2002512602A/en active Pending
- 1998-02-13 ES ES98917563T patent/ES2182297T3/en not_active Expired - Lifetime
- 1998-02-13 CA CA2273821A patent/CA2273821C/en not_active Expired - Fee Related
- 1998-02-13 AU AU70746/98A patent/AU7074698A/en not_active Abandoned
- 1998-12-16 US US09/212,971 patent/US6107041A/en not_active Expired - Lifetime
-
2000
- 2000-07-14 US US09/617,053 patent/US6300492B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/974,592 patent/US7087584B2/en not_active Expired - Fee Related
-
2006
- 2006-03-20 US US11/384,739 patent/US20060189563A1/en not_active Abandoned
- 2006-08-25 US US11/509,784 patent/US20070203088A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/111,013 patent/US20090142334A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006255A2 (en) * | 1995-08-04 | 1997-02-20 | University Of Ottawa | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
WO1997026331A2 (en) * | 1996-01-19 | 1997-07-24 | University Of Ottawa | Use of neuronal apoptosis inhibitor protein (naip) |
WO1998022131A2 (en) * | 1996-11-15 | 1998-05-28 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
Non-Patent Citations (1)
Title |
---|
P. LISTON ET AL.: "SUPPRESSION OF APOPTOSIS IN MAMMALIAN CELLS BY NAIP AND A RELATED FAMILY OF IAP GENES.", NATURE, vol. 379, 25 January 1996 (1996-01-25), LONDON GB, pages 349 - 353, XP002032296 * |
Also Published As
Publication number | Publication date |
---|---|
US6107041A (en) | 2000-08-22 |
PT991421E (en) | 2002-12-31 |
US6300492B1 (en) | 2001-10-09 |
US7087584B2 (en) | 2006-08-08 |
US20020120121A1 (en) | 2002-08-29 |
DE69807878D1 (en) | 2002-10-17 |
DE69807878T2 (en) | 2003-05-28 |
US20090142334A1 (en) | 2009-06-04 |
US6133437A (en) | 2000-10-17 |
ATE223727T1 (en) | 2002-09-15 |
EP0991421A2 (en) | 2000-04-12 |
EP0991421B1 (en) | 2002-09-11 |
JP2002512602A (en) | 2002-04-23 |
US20070203088A1 (en) | 2007-08-30 |
CA2273821C (en) | 2010-08-24 |
CA2273821A1 (en) | 1998-08-20 |
ES2182297T3 (en) | 2003-03-01 |
US20060189563A1 (en) | 2006-08-24 |
WO1998035693A2 (en) | 1998-08-20 |
AU7074698A (en) | 1998-09-08 |
EP1277836A1 (en) | 2003-01-22 |
DK0991421T3 (en) | 2002-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998035693A3 (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease | |
WO2004046342A3 (en) | Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas | |
IL153052A0 (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
WO1997033909A3 (en) | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer | |
WO2004008099A3 (en) | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES | |
AU4073297A (en) | Methods and compositions for the detection of cervical cancer | |
WO2003004989A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
ATE454468T1 (en) | DETECTION OF THE INSTABILITY OF MICROSATELLITES AND USE THEREOF IN TUMOR DIAGNOSIS | |
WO2003000012A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer | |
WO2004067570A3 (en) | Prostate cancer diagnosis and treatment | |
WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
DE60137264D1 (en) | MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC) | |
WO2004046332A3 (en) | Amplified genes involved in cancer | |
WO2002064839A3 (en) | Methods for the diagnosis and treatment of tumors employing the hepsin gene | |
WO2000035950A3 (en) | Reagents and methods useful for detecting diseases of the breast | |
WO2001018046A3 (en) | Ovarian tumor sequences and methods of use therefor | |
WO1999028461A3 (en) | Methods and means for inducing apoptosis by interfering with bip-like proteins | |
WO2001013117A3 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
WO2003044161A3 (en) | Gene amplification and overexpression in cancer | |
WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
WO2004069860A3 (en) | Isg15-conjugated proteins | |
WO2002092765A3 (en) | Novel telomerase inhibitors and uses therefor | |
WO1999018210A3 (en) | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer | |
IL138021A0 (en) | High affinity humanized anti-tag-72 monoclonal antibodies | |
ZA902425B (en) | Retinoblastoma gene product and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2273821 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998917563 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998917563 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998917563 Country of ref document: EP |